potential implication results similar approaches targeting amyloid beta al sandrock biogen head research development chief medical officer said interview new results team find previous instance trial stopped futility turned positive pinch not believe sandrock said amazing change march happy know people mild cognitive impairment felt like let june biogen analyzed data set researchers started realize different picture emerging aducanumab sandrock said reason changes biogen study late game initially company worried potential effect brain swelling limited dosage drug later patients allowed receive higher doses medicine retrospect results futility analysis incorrect sandrock said smaller dataset looked patients exposure high dose aducanumab essence